Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Histone acetylation-mediated regulation of the Hippo pathway.

Basu D, Reyes-Múgica M, Rebbaa A.

PLoS One. 2013 May 6;8(5):e62478. doi: 10.1371/journal.pone.0062478. Print 2013.

2.

Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways.

Basu D, Lettan R, Damodaran K, Strellec S, Reyes-Mugica M, Rebbaa A.

Mol Cancer Ther. 2014 Jun;13(6):1457-67. doi: 10.1158/1535-7163.MCT-13-0918. Epub 2014 Apr 2.

3.

The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition.

Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, Lei QY, Guan KL.

J Biol Chem. 2012 Jul 27;287(31):26245-53. doi: 10.1074/jbc.M112.382036. Epub 2012 Jun 12.

4.

Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation.

Lugrin J, Ding XC, Le Roy D, Chanson AL, Sweep FC, Calandra T, Roger T.

Biochim Biophys Acta. 2009 Nov;1793(11):1749-58. doi: 10.1016/j.bbamcr.2009.09.007. Epub 2009 Sep 10.

5.

Troglitazone inhibits histone deacetylase activity in breast cancer cells.

Davies GF, Ross AR, Arnason TG, Juurlink BH, Harkness TA.

Cancer Lett. 2010 Feb 28;288(2):236-50. doi: 10.1016/j.canlet.2009.07.011. Epub 2009 Aug 20.

PMID:
19699029
6.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S.

Mol Cancer Ther. 2008 Jun;7(6):1494-505. doi: 10.1158/1535-7163.MCT-08-0183.

7.

Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.

Chen M, Wang M, Xu S, Guo X, Jiang J.

Oncotarget. 2015 Dec 29;6(42):44466-79. doi: 10.18632/oncotarget.6298.

8.

Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.

Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y.

Int J Oncol. 2006 Jul;29(1):269-78.

PMID:
16773209
9.

Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs).

Mo JS, Yu FX, Gong R, Brown JH, Guan KL.

Genes Dev. 2012 Oct 1;26(19):2138-43. doi: 10.1101/gad.197582.112. Epub 2012 Sep 12.

10.

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C.

Endocr Relat Cancer. 2013 May 21;20(3):321-37. doi: 10.1530/ERC-12-0240. Print 2013 Jun.

11.

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.

Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, Hyun YL, Choi J.

Breast Cancer Res Treat. 2011 Nov;130(2):365-75. doi: 10.1007/s10549-010-1310-4. Epub 2010 Dec 24.

PMID:
21184271
12.

Zac1 is a histone acetylation-regulated NF-κB suppressor that mediates histone deacetylase inhibitor-induced apoptosis.

Shu G, Tang Y, Zhou Y, Wang C, Song JG.

Cell Death Differ. 2011 Dec;18(12):1825-35. doi: 10.1038/cdd.2011.51. Epub 2011 May 6.

13.

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.

Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D, Pan S, Liu J, Jiang H, Liu L.

Mol Cancer. 2013 Oct 5;12(1):114. doi: 10.1186/1476-4598-12-114.

14.
15.

Carbon monoxide induces chromatin remodelling to facilitate endothelial cell migration.

Li M, Gallo D, Csizmadia E, Otterbein LE, Wegiel B.

Thromb Haemost. 2014 May 5;111(5):951-9. doi: 10.1160/TH13-09-0748. Epub 2014 Jan 30.

PMID:
24477332
16.

Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.

Rashidian J, Le Scolan E, Ji X, Zhu Q, Mulvihill MM, Nomura D, Luo K.

Sci Signal. 2015 Feb 10;8(363):ra14. doi: 10.1126/scisignal.2005735.

17.

Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells.

Liu ZC, Chen XH, Song HX, Wang HS, Zhang G, Wang H, Chen DY, Fang R, Liu H, Cai SH, Du J.

Cell Tissue Res. 2014 Nov;358(2):491-502. doi: 10.1007/s00441-014-1953-2. Epub 2014 Aug 16.

PMID:
25124796
18.

The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.

Mostovich LA, Prudnikova TY, Kondratov AG, Gubanova NV, Kharchenko OA, Kutsenko OS, Vavilov PV, Haraldson K, Kashuba VI, Ernberg I, Zabarovsky ER, Grigorieva EV.

Epigenetics. 2012 Aug;7(8):930-9. doi: 10.4161/epi.21199. Epub 2012 Jul 18.

19.

DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation.

Milutinovic S, Brown SE, Zhuang Q, Szyf M.

J Biol Chem. 2004 Jul 2;279(27):27915-27. Epub 2004 Apr 15.

20.

The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase.

Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei QY, Guan KL.

J Biol Chem. 2010 Nov 26;285(48):37159-69. doi: 10.1074/jbc.M110.152942. Epub 2010 Sep 21.

Supplemental Content

Support Center